IntelGenx to file NDA amendment in first quarter
June 22, 2010 by leonardzehr · Leave a Comment
IntelGenx Technologies (TSX-V:IGX) has met with the FDA to discuss a complete response letter received in February about its new drug application for its antidepressant CPI-300 and expects to file an amendment to the NDA in the first quarter of 2011. CPI-300 is a novel, high strength of Bupropion HCl, the active ingredient in Wellbutrin [...]
Listen to BioTuesdays 
